• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Recent FDA approvals

News
Article

Desmopressin tablets 0.1 and 0.2 mg (equiv to DDAVP tablets).

First-time generic approvals

Desmopressin tablets 0.1 and 0.2 mg (equiv to DDAVP tablets)
BARR

Isoniazid injection 100 mg/mL packaged in 10 mL multiple-dose vials (equiv to Nydrazid injection)
SABEX 2002

Alclometasone cream 0.05% (equiv to Aclovate cream)
ALTANA

Fexofenadine capsules 60 mg (equiv to Allegra capsules)
BARR

Doxycycline tablets and capsules 150 mg (equiv to Monodox capsules)
PAR

Pyridostigmine tablets 30 mg (equiv to pyridostigmine tablets)
BARR

Rifampin and isoniazid capsules 300/150 mg (equiv to Rifamate capsules)
WEST-WARD

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.